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With the widespread use of combination antiretroviral
agents, the incidence of HIV-associated nephropathy has
decreased. Currently, HIV-infected patients live much longer
and often suffer from comorbidities such as diabetes mellitus.
Recent epidemiological studies suggest that concurrent HIV
infection and diabetes mellitus may have a synergistic effect
on the incidence of chronic kidney disease. To address this,
we determined whether HIV-1 transgene expression
accelerates diabetic kidney injury using a diabetic HIV-1
transgenic (Tg26) murine model. Diabetes was initially
induced with low-dose streptozotocin in both Tg26 and wild-
type mice on a C57BL/6 background, which is resistant to
classic HIV-associated nephropathy. Although diabetic
nephropathy is minimally observed on the C57BL/6
background, diabetic Tg26 mice exhibited a significant
increase in glomerular injury compared with nondiabetic
Tg26 mice and diabetic wild-type mice. Validation of
microarray gene expression analysis from isolated glomeruli
showed a significant upregulation of proinflammatory
pathways in diabetic Tg26 mice. Thus, our study found that
expression of HIV-1 genes aggravates diabetic kidney disease.
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published online 16 January 2013
KEYWORDS: diabetic nephropathy; glomerulopathy; HIV
It had been nearly three decades since the first published
reports of HIV-associated nephropathy (HIVAN), an aggres-
sive form of focal segmental glomerulosclerosis in patients
with AIDS.1–3 Within years, HIVAN was recognized not only
as an AIDS-defining illness4 but also as a disease
predominant in patients of African descent.5 The incidence
of HIVAN and the progression to end-stage renal disease
continued to rise until the advent and use of combination
antiretroviral therapy (cART) in the mid 1990s. In fact, with
the widespread use of cART, the incidence of end-stage renal
disease attributed to HIVAN has reduced to approximately
800–900 cases per year in the United States. However, the
prevalence of end-stage renal disease in this population has
continued to rise, likely because of an increase in patient
survival.6 In addition, as patients live longer with HIV, they
are at increased risk for comorbidities such as hypertension
and diabetes mellitus (DM).7
Several studies have shown that many patients who
undergo a clinically indicated kidney biopsy are diagnosed
with a non-HIVAN-related kidney disease in the post-ART
era, ranging from immune complex–mediated kidney diseases
to arterionephrosclerosis, and diabetic nephropathy.8–10
Studies such as these suggest that the spectrum of kidney
disease has changed considerably in the last 15 years. With
this change, the clinical course of kidney disease in the cART
era has been more indolent, a slow progressive decline in
kidney function with lower levels of proteinuria. Although
the Office of AIDS Research Advisory Council has clearly
stated in the 2012 guidelines that the presence of HIVAN is
an indication for initiation of cART regardless of CD4 count,
the decision to start cART in non-HIVAN-related kidney
disease independent of other factors remains unclear
(Aidsinfo.nih.gov).
Studies have estimated that nearly 15% of HIV-1-infected
patients have comorbid DM. In fact, several studies have
suggested that concurrent HIV and DM may have an additive
effect on the incidence of chronic kidney disease (CKD).11,12
For example, Choi et al.11 showed that HIV and DM may
have a synergistic effect on the incidence of end-stage renal
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disease in both Caucasians and African Americans.
Specifically, in a recent study using the Veterans Aging
Cohort Study database, we demonstrated that concurrent
occurrence of HIV and DM has a greater effect on the risk of
CKD progression compared with the occurrence of either
condition alone.12
Since the derivation of the HIV-1 transgenic mice bearing
a defective provirus lacking gag-pol (Tg26) in the early 1990s,
studies have shown that classical features of HIVAN are
exhibited primarily on the FVB background strain.13 These
Tg26 mice at an early age exhibit nephrotic range proteinuria,
podocyte dedifferentiation and proliferation, collapsing focal
segmental glomerulosclerosis, and microcystic tubular
dilatation and injury, consistent with the features observed
in HIVAN.13 However, these changes are not observed in
Tg26 mice on the C57BL/6 background. Therefore, Tg26
mice on the C57BL/6 background strain were used to study
non-HIVAN kidney disease.
Although epidemiological studies suggest that HIV
infection is associated with the progression of CKD in
patients with DM, the cause–effect relationship and the
mechanism behind this association have yet to be described.
Previous studies suggest that chronic inflammation con-
tributes to disease pathogenesis in both diabetic nephropathy
and HIVAN.14,15 Thus, we hypothesized that chronic
infection with HIV-1 leads to a proinflammatory state,
thereby accelerating diabetic glomerular disease. Here, we
demonstrate that streptozotocin (STZ)-induced diabetic
mice exhibit more glomerular injury in the presence of
HIV-1 transgene expression. We also provide evidence
suggesting that this process is associated with an
upregulation of proinflammatory pathways.
RESULTS
Diabetic Tg26 mice exhibit an increase in glomerular injury
C57BL/6 mice are typically resistant to STZ-induced diabetic
nephropathy16 and Tg26 mice on the C57BL/6 background
are resistant to HIVAN, typically observed on the FVB
background.17,18 To study non-HIVAN-related kidney
disease, Tg26 mice on the C57BL/6 background were used
to test our hypothesis. To confirm that STZ treatment
induced DM in mice, physiological parameters of the mice in
each of the four groups were measured (Supplementary Table
S1 online). Also, to verify that HIV-1 viral gene expression
was unchanged after induction of diabetes with STZ, nef
mRNA expression was measured using real-time PCR
(Supplementary Figure S1 online). A lack of change in nef
expression in Tg26 mice with or without diabetes suggests
that an increase in glomerular injury observed in diabetic
Tg26 mice was not a result of an increase in local viral gene
expression. nef mRNA expression was undetectable in wild-
type (WT) mice (data not shown). At 6 months of age,
diabetic Tg26 mice exhibited a significant increase in
proteinuria as compared with all other groups (Figure 1).
Histological changes by light and electron microscopy at low-
and high-power magnification are shown at 6 months of age
(Figure 2). Histologically and by quantification, glomerular
size, mesangial expansion, and glomerular basement mem-
brane (GBM) thickening were significantly increased in
diabetic Tg26 mice compared with all other groups (Figures
3a–c). In addition, diabetic and nondiabetic Tg26 mice had a
significant increase in foot process effacement as compared
with WTmice with or without diabetes (Figure 3d). Also, the
podocyte number per glomerulus was significantly reduced
in diabetic Tg26 mice as compared with all other groups
(Figure 3e). Combined, these findings suggest that expression
of HIV-1 transgene in C57BL/6 diabetic mice induces
glomerular injury, typically observed in early diabetic
nephropathy.
Increase in the activation of pathways involved in
inflammation from enrichment analysis of gene array data in
diabetic Tg26 mice
To identify unique or synergistic pathways from the
differentially expressed genes in diabetic Tg26 mice, we used
oligonucleotide microarrays to profile gene expression in
glomeruli isolated from WT mice, diabetic WT mice, Tg26
mice, and diabetic Tg26 mice. Similarly, microarrays from
patients with diabetic nephropathy (glomeruli) were re-
trieved from the Woroniecka Database in Nephromine
(http://www.nephromine.org). Also, to compare changes in
gene expression in known murine models of diabetic
nephropathy, we acquired microarrays deposited in Gene
Expression Omnibus (GSE710).19 For the differentially
expressed genes in each experimental group, we performed
gene enrichment analysis using the Expression2Kinases
software (www.maayanlab.net/X2K/) program to identify
pathways involved in inflammation and fibrosis. A combina-
tion of gene-list libraries such as Wikipathway, MGI
Mammalian Phenotype, KEGG Pathway, and GO molecular
function revealed a significant increase in the activation of
pathways involving inflammation in diabetic Tg26 mice,
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Figure 1 | Diabetic HIV-1 transgenic (Tg26) mice exhibit an
increase in proteinuria. Wild-type (WT) and Tg26 mice were treated
with streptozotocin (STZ). Urine was collected at baseline before STZ
or sodium citrate buffer injection, and the urine protein/creatinine
ratio was checked monthly. Urine protein/creatinine ratio at 6
months of age (n¼ 6, *Po0.01 versus mice treated with sodium
citrate buffer).
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consistent with those observed in human diabetic nephro-
pathy and a known murine model of diabetic nephropathy
(db/db mice) (Figure 4). These findings suggest that HIV-1
and diabetes may have a synergic effect on the induction of a
proinflammatory state leading to the pathogenesis observed
in diabetic Tg26 mice.
Upregulation of proinflammatory genes is validated by real-
time PCR
To validate the activation of proinflammatory pathways from
gene enrichment analysis, primers for selected genes
implicated in inflammation were designed (Supplementary
Table S2 online) and quantitative real-time PCR was
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Figure 2 | Diabetic HIV-1 transgenic (Tg26) mice exhibit an increase in glomerular injury. Paraffin-embedded sections were stained with
periodic acid–Schiff (PAS) and images were taken at low power (20) and high power (40). Ultrastructural changes are shown at low power
(3000) and high power (10,000) by transmission electron microscopy.
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Figure 3 | Quantification of glomerular injury in diabetic HIV-1 transgenic (Tg26) mice. Quantification of (a) glomerular volume,
(b) glomerular basement membrane (GBM) thickness, (c) and mesangial expansion is shown (n¼ 3, *Po0.0001 versus all other groups).
(d) Quantification of podocyte effacement is shown (n¼ 4, *Po0.0001 versus all groups, **Po0.0001 versus diabetic and nondiabetic wild-type
(WT) mice). (e) Quantification of podocyte number is shown (n¼ 3, *Po0.0001 versus all groups).
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performed. These proinflammatory genes include VCAM1,
FAS, FASL, c-MYC, CCL2, and ICAM1. Real-time PCR
revealed a significant increase in these proinflammatory genes
in isolated glomeruli of diabetic Tg26 mice as compared with
all other groups (Figure 5). Combined, these findings confirm
that a local proinflammatory state is associated with the
glomerular disease observed in diabetic Tg26 mice.
Circulating levels of inflammatory markers
To clarify the role of circulating inflammatory markers in the
progression of kidney disease observed in diabetic Tg26 mice,
serum was collected from all four groups of mice at the time
that they were being killed. The sandwich enzyme immu-
noassay technique was used to measure the circulating levels
of TNFR1, TNFR2, and IL-6. A significant increase in TNFR1
and IL-6 serum levels was observed in diabetic-only, Tg26-
only, and diabetic Tg26 mice as compared with WT mice
(Figures 6a, c). This finding was not observed in circulating
levels of TNFR2 (Figure 6b). Although the activation of local
inflammatory genes is predominantly observed in diabetic
Tg26 mice, elevation of circulating inflammatory cytokines
may still contribute to the glomerular changes observed in
this group.
Upregulation of profibrotic genes in diabetic Tg26 mice by
real-time PCR
To assess for the activation of profibrotic pathways, primers
for genes involved in mesangial expansion were designed
(Supplementary Table S2 online) and quantitative real-time
PCR was performed. These genes include TGFb1, CTGF,
Collagen Type I, and a-SMA. Real-time PCR from glomerular
extracts revealed a significant increase in the mRNA
expression of these genes in diabetic Tg26 mice as compared
with all other groups (Figure 7).
Collagen Type IV expression is increased in diabetic Tg26
mice
Collagen Type IV is constitutively expressed in the GBM and
in the mesangial matrix.20 As we observed an increase in
GBM thickness and mesangial matrix in diabetic Tg26 mice,
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Figure 4 | Activation of pathways involved in inflammation from gene enrichment analysis in diabetic HIV-1 transgenic (Tg26) mice,
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Type IV collagen expression was measured to assess for
changes in expression and distribution. In isolated glomeruli,
Collagen Type IV mRNA expression was significantly
increased in diabetic Tg26 mice (Figure 8a). These findings
were validated by immunofluorescence qualitatively and
quantitatively (Figures 8b and c).
Smad3 phosphorylation is increased in diabetic Tg26 mice
Since there was an upregulation of local profibrotic genes
involved in matrix expansion and GBM thickening, we
assessed for activation of the TGFb pathway by measuring
Smad3 phosphorylation from the isolated renal cortex.
Smad3 phosphorylation was significantly increased in
diabetic Tg26 mice (Figure 9a). These findings were
quantified by densitometric analysis (Figure 9b). Combined,
these findings suggest a significant activation of the
profibrotic pathway in diabetic Tg26 mice.
DISCUSSION
A large body of epidemiological studies indicates that the
spectrum of HIV-related kidney disease has changed
markedly in the last decade. Further, as patients with HIV
live longer, they are more susceptible to non-HIVAN-related
kidney diseases such as diabetic nephropathy. Although a
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diagnosis of HIVAN is an indication for cART initiation
regardless of CD4 count, it remains unclear whether this
remains applicable to patients with non-HIVAN-related
kidney disease. Further, mechanisms that contribute to this
disease process have yet to be described. Here, we provide
evidence that HIV-1 may contribute to or aggravate early
stages of glomerular disease observed in diabetic nephropathy
probably through activation of proinflammation pathways.
Although epidemiological studies suggest that HIV infec-
tion is associated with the progression of diabetic nephro-
pathy, the cause–effect relationship remains unclear. We
provide direct evidence showing that expression of HIV-1
transgene in diabetic mice contributes to a significant increase
in glomerular injury, mimicking early diabetic nephropathy.
The observed changes in glomerular injury in the diabetic
Tg26 mice were on the C57BL/6 background, a strain typically
resistant to diabetic nephropathy and HIVAN.16–18 Although
these findings suggest that HIV infection contributes to the
acceleration of diabetic nephropathy, we acknowledge that the
pathology is not overwhelming. In fact, these findings are
more representative of an early stage of glomerular disease
and are likely attributable to the sclerosis-resistant mouse
background, C57BL/6.21 Diabetes-related glomerulosclerosis
is typically observed in sclerosis-prone genetic
backgrounds.16,22,23 Further studies using a similar approach
in sclerosis-prone genetic backgrounds will be required to
determine the progression to advanced glomerulosclerosis.
Nevertheless, we believe that the changes observed in this
study are unique and likely attributable to the presence of
concomitant diabetes and HIV-1 transgene expression,
especially as these pathological changes are typically not
observed on this background.
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To identify genes or synergistic pathways that have a role in
the disease progression observed in diabetic Tg26 mice,
microarray expression studies were performed. Using the gene
enrichment analysis tool from the Expression2Kinases soft-
ware,24 we confirmed that proinflammatory genes were
significantly upregulated in diabetic Tg26 mice, suggesting
an underlying mechanism mediating the observed disease
process. Similar inflammatory pathways were also activated in
human diabetic nephropathy as well as in a known murine
model of diabetic nephropathy. This suggests that diabetic
nephropathy may in part be activated by complementing these
inflammatory pathways in C57BL/6 mice in the setting of
concomitant diabetes and HIV-1 transgene expression. Also,
the activation of inflammatory pathways with HIV infection is
consistent with previous studies.25 Further, HIV-associated
inflammation has been implicated in premature onset of other
end-organ abnormalities.25,26 Finally, we observed an
upregulation of genes involved in GBM thickening and
mesangial expansion, as well as the activation of the TGFb
pathway, in diabetic Tg26 mice. Therefore, we speculate that a
state of local chronic inflammation induced by HIV accelerates
diabetic kidney disease.
Circulating levels of TNFR1 have been associated with the
progression of diabetic nephropathy.27,28 Minimal, yet signi-
ficant, elevation in serum TNFR1 and IL-6 may contribute to
the early glomerular changes observed in diabetic Tg26 mice.
However, it is likely not primarily responsible for the
histological changes observed in the diabetic Tg26 mice, as
a significant increase in serum TNFR1 and IL-6 levels was
also observed in diabetic-only and Tg26-only mice. The role
of HIV-induced systemic inflammatory response in kidney
injury still remains to be defined until other circulating
inflammatory markers are measured. However, in HIVAN,
reciprocal renal transplantation between WT and Tg26 mice
revealed that intrarenal expression of HIV-1 genes, not
systemic inflammation, is responsible for progression to
HIVAN.29 Therefore, the kidney has been considered a reser-
voir for HIV-1. In this study, a lack of change in nef expres-
sion in Tg26 mice with or without diabetes suggests that an
increase in glomerular injury observed in diabetic Tg26 mice
is not a result of an increase in local viral gene expression.
In summary, we report a murine model to study non-
HIVAN-related kidney disease. Our studies suggest that the
presence of the HIV-1 transgene accelerates the progression of
diabetic nephropathy. Further, the activation of local proin-
flammatory pathways in the setting of concurrent diabetes and
HIV-1 transgene expression may contribute to the glomerular
injury observed in this murine model. This study provides a
novel insight into the potential mechanisms involved in the
progression of non-HIVAN-related kidney disease.
MATERIALS AND METHODS
Genotyping of Tg26 mice
The Mount Sinai School of Medicine Animal Institute Committee
approved all animal studies, and the NIH Guide for the Care and
Use of Laboratory Animals was followed strictly. Derivation of a
transgenic mouse line (Tg26 mice) that bears a defective HIV-1
provirus lacking gag-pol (Tg26) has been described.13 Tg26 mice in
the FVB/N background were backcrossed six generations to a
C57BL/6 background. WTmice generated from the same litter of Tg26
mice were used as controls in the studies. Genotyping by tail prep and
PCR was performed at 2 weeks of age as previously described.30
Low-dose STZ-induced diabetes
Induction of diabetes using STZ has been described previously.31
Briefly, on day 1, Tg26 and WTmice at 6 weeks of age were initially
deprived of food for 4 hours. Thereafter, low-dose STZ (50mg/kg)
in 50mmol/l sodium citrate buffer (pH 5.4) was administered
intraperitoneally. STZ was administered similarly at the same dose
on days 2–5. On day 14, all mice were deprived of food for 6 h and
fasting blood glucose level from the tail vein was checked using the
One Touch Blood Glucose Monitoring System. Repeat fasting blood
glucose measurements were taken monthly to verify hyperglycemia.
Diabetes mellitus was defined as sustained fasting blood glucose
above 250mg/dl at two distinct time points 2 weeks post STZ
injection.31 All mice were killed at 6 months of age.
Measurement of urine albumin and creatinine
Urine albumin was quantified by ELISA using a kit from Bethyl
Laboratory (Houston, TX). Urine creatinine levels were measured in
the same samples using the QuantiChrom Creatinine Assay Kit
(DICT-500) (BioAssay Systems, Hayward, CA) according to the
manufacturer’s instructions. The urine albumin excretion rate was
expressed as the ratio of albumin to creatinine.
Bright-field light microscopy and morphometric studies
Mice were perfused with Hank’s buffered salt solution (HBSS) and
fixed with 4% paraformaldehyde overnight. Kidney tissue was
embedded in paraffin by American Histolabs (Gaithersburg, MD)
and 3 mm-thick sections were stained with periodic acid–Schiff
(Sigma, St Louis, MO).
Estimation of glomerular volume and mesangial area was made
as previously described.32,33 Briefly, digitized images were scanned
and profile areas were traced using ImageJ. The mean glomerular
tuft volume was determined from the mean glomerular cross-
sectional area by light microscopy. The glomerular cross-sectional
area was calculated on the basis of the average area of 30 glomeruli
in each group, and glomerular tuft volume was calculated using the
following equation:
GV¼ b
k
GA3/2
(b¼ 1.38, the shape coefficient of spheres (the idealized shape of
glomeruli), and k¼ 1.1, the size distribution coefficient). Also,
mesangial expansion was defined as a periodic acid–Schiff-positive
and nuclei-free area in the mesangium. Quantification of mesangial
expansion was based on 20 glomeruli cut at the vascular pole in each
group.
Quantification of podocyte number per glomerulus was
determined using Wilm’s tumor-1-stained podocytes. First, kidney
sections from these mice were prepared in an identical manner.
Thereafter, 4 mm-thick sections were stained with rabbit anti-WT-1
(Novus, Littleton, CO) as previously described.34 Counting of
podocytes and quantification of glomerular area and volume were
performed using ImageJ and by the method standardized by Animal
Models of Diabetic Complications Consortium.32
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Transmission electron microscopy and morphometric studies
Mice were perfused with HBSS and immediately fixed in 2.5%
glutaraldehyde for electron microscopy. Sections were mounted on a
copper grid and photographed under a Hitachi H7650 microscope
(Tokyo, Japan).
Quantification of podocyte effacement was performed as pre-
viously described.35 Briefly, negatives were digitized, and images
with a final magnitude of approximately X15,000 were obtained.
ImageJ 1.26t software (National Institute of Health, rsb.info.nih.gov/ij)
was used to measure the length of the peripheral GBM, and the number
of slit pores overlying this GBM length was counted. The arithmetic
mean of the foot process width (WFP) was calculated as follows:
WFP¼ p
4

P
GBM length
P
slits
(Sslits indicates the total number of slits counted, SGBM length
indicates the total GBM length measured in one glomerulus, and p/4
is the correction factor for the random orientation by which the foot
processes were sectioned).35
Sections stained with uranyl acetate and lead citrate were
mounted on a copper grid and photographed under a JEOL 1011
transmission electron microscope using Gatan imaging software
(Gatan, Warrendale, PA). Quantification of GBM thickness was
performed as previously described.36 The thickness of multiple
capillaries was measured in 6–8 glomeruli per mouse (n¼ 3 per
group). A mean of 114 measurements was taken per mouse (from
podocyte to endothelial cell membrane) at random sites where GBM
was displayed in the best cross-section.
Microarray gene expression and gene ontology analysis
Gene expression profiling using Illumina (San Diego, CA) gene
expression beadchips was performed at the Mount Sinai Institution
Microarray Core Facility. The Illumina MouseWG-6 v2.0 was used
to profile gene expression in the glomeruli from all four experi-
mental groups: WT mice, diabetic-only mice, Tg26-only mice, and
diabetic Tg26 mice. In brief, the raw data were processed using a
Python program in which quantile normalization was performed.
The unpaired t-test was used to assess statistical significance between
the groups. A list of differentially expressed genes was generated for
each group using a cutoff of Po0.05 with the Benjamini–Hochberg
correction. Enrichment analysis was performed using the Expression2-
Kinases software, and Fisher’s exact test was used to determine the
terms that were overrepresented among the differentially expressed
genes in each of the groups compared with untreated WTmice.24
Isolation of glomeruli from mice for RNA extraction
Mouse glomeruli were isolated as described.37 In brief, animals were
perfused with HBSS containing 2.5mg/ml iron oxide and 1% bovine
serum albumin. At the end of perfusion, kidneys were removed,
decapsulated, minced into 1-mm3 pieces, and digested in HBSS con-
taining 1mg/ml collagenase A and 100U/ml deoxyribonuclease I.
Digested tissue was then passed through a 100-mm cell strainer and
collected by centrifugation. The pellet was resuspended in 2ml of HBSS
and glomeruli were collected using a magnet. The purity of the glo-
meruli was verified by microscopy. Total RNAwas isolated from kidney
glomeruli of mice using TRIzol (Invitrogen, Grand Island, NY).
Real-time PCR
Total RNA was extracted using TRIzol (GIBCO Life Technology,
Grand Island, NY). First-strand cDNAwas prepared from total RNA
(1.5mg) using the SuperScript III First-Strand Synthesis Kit (Invitrogen),
and cDNA (1 ml) was amplified in triplicate using SYBR GreenER
qPCR Supermix on an ABI PRISM 7900HT (Applied Biosystems,
Foster City, CA). Primers were designed using PrimerBlast (http://
www.ncbi.nlm.nih.gov/tools/primer-blast/) and purchased through
Sigma (Supplementary Table 2 online), with the exception of previously
published primers for nef and GAPDH.7,38 Light cycler analysis software
(Carlsbad, CA) was used to determine crossing points using the second
derivative method. Efficiency was calculated for all the designed primers
using the relative standard curve method. Data were normalized to the
housekeeping gene (GAPDH) and presented as fold increase compared
with RNA isolated from WT animals using the Pfaffl method.39
Measurement of inflammation-related serum markers
Initially, 200ml of blood was collected from mice at the time that
they were being killed. Blood samples were allowed to clot for 2 h at
room temperature before centrifuging for 20min at 2000 g. Serum
was extracted and quantitative sandwich enzyme immunoassay was
performed as per manufacturers’ protocol to quantify serum
TNFR1, TNFR2, and IL-6 levels (no. MRT10, no. MRT20, no.
M6000B; R&D systems, Minneapolis, MN).
Immunofluorescence
Kidney sections from these mice were prepared in an identical
manner. Immunostaining was performed using rabbit anti-collagen
IV (Santa Cruz, Santa Cruz, CA). After washing, sections were
incubated with a fluorophore-linked secondary antibody (Alexa
Fluor 488 anti-rabbit IgG from Invitrogen). After staining, slides
were mounted in Aqua Poly/Mount (Polysciences, Warrington, PA)
and photographed under an AxioVision IIe microscope with a
digital camera (Munchen, Germany).
Quantification of immunofluorescence
After sections were stained with anti-Collagen Type IV antibody, nega-
tives were digitized, and images with a final magnitude ofBX40 were
obtained. ImageJ 1.26t software (National Institute of Health,
rsb.info.nih.gov/ij) was used to measure the level of immunostaining
in the glomeruli. First, the images were converted to an 8-bit
grayscale. Next, the glomerular region was selected for measurement
of area and integrated density. Then, the background intensity was
measured by selecting three distinct areas in the background with no
staining. The corrected optical density was determined as follows:
COD¼ IDðAMGVÞ
(ID is the integrated density of the selected glomerular region; A
is the area of the selected glomerular region; and MGV is the mean
gray value of the background readings).40
Western blot
Glomeruli were lysed with a buffer containing 1% Triton, a protease
inhibitor cocktail, and tyrosine and serine-threonine phosphoryla-
tion inhibitors. Lysates were subjected to an immunoblot analysis
using rabbit anti-phospho Smad3 (Cell Signaling, Danvers, MA),
rabbit anti-total Smad3 (Cell Signaling), and mouse anti-b-actin
antibodies (Abcam, Cambridge, MA). Densitometric analysis for
quantification was performed as previously described.41
Statistical analysis
Data were expressed as mean±s.e.m. (X±s.e.m.). The unpaired
t-test was used to analyze data between two groups. The analysis of
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variance followed by Bonferroni’s correction was used when more
than two groups were present. All experiments were repeated at least
three times, and representative experiments are shown. Statistical
significance was considered when Po0.05.
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